Track topics on Twitter Track topics that are important to you
DelveInsight's Moderate Psoriasis Epidemiology Forecast, 2025 provides an overview of the epidemiology trends of Moderate Psoriasis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Moderate Psoriasis. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Moderate Psoriasis. The report contains the targeted patient populations and the forecast methodology.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse Forecast model analysis by DelveInsight team of industry experts.
Key Coverage and Benefits
The Report includes the prevalent population and how will it change over the next eight years.
Coverage of key Moderate Psoriasis subpopulations and its prevalent or incident cases
Prevalent or incident cases segmented by age and sex.
The key differences in epidemiology patterns across the seven market segments.
Reasons to buy
Developing business strategies by understanding the trends shaping and driving the global Moderate Psoriasis market.
Identifying prevalent patient populations as well as risk factors in the global Moderate Psoriasis market will help to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Moderate Psoriasis therapeutics in each of the markets covered.
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...